Blood and Immunity Practice Questions

Q: Oedema occurs when plasma protein level is below which value?

5 mg/dl. **Explanation:** The development of oedema is primarily governed by **Starling’s Forces**, which regulate fluid exchange between capillaries and the interstitium. The two main opposing forces are Capillary Hydrostatic Pressure (pushing fluid out) and **Plasma Colloid Osmotic Pressure (COP)** (pulling fluid in). **Why 5 mg/dl is correct:** Plasma proteins, specifically **Albumin** (which contributes 70-80% of the COP), are responsible for maintaining an oncotic pressure of approximately 25-28 mmHg. When total plasma protein levels fall below **5 g/dl** (specifically when albumin falls below **2.5 g/dl**), the COP decreases significantly. This allows hydrostatic pressure to dominate, leading to the excessive filtration of fluid into the interstitial space, resulting in clinical oedema. **Analysis of Incorrect Options:** * **A & D (8 mg/dl & 10 mg/dl):** These values are within or above the normal range for total plasma proteins (Normal: 6–8 g/dl). At these levels, oncotic pressure is sufficient to prevent fluid leakage. * **B (2 mg/dl):** While oedema certainly occurs at 2 g/dl, this is a state of severe hypoproteinemia (often seen in advanced Nephrotic syndrome or Kwashiorkor). The threshold or "critical level" at which oedema *begins* to manifest is 5 g/dl. **High-Yield Clinical Pearls for NEET-PG:** * **Hypoproteinemic Oedema:** Characteristically presents as **pitting oedema** and is often first seen in lax tissue like the eyelids (periorbital oedema) or dependent parts (feet). * **Albumin vs. Globulin:** Albumin is more important for COP than globulin because it has a lower molecular weight (more molecules per unit weight) and a higher concentration. * **Mnemonic:** Remember the **"Rule of 5 & 2.5"**—Oedema occurs when Total Protein < 5 g/dl or Albumin < 2.5 g/dl.

Q: Which of the following anticoagulants prevent clotting of blood in the normal vascular system?

Antithrombin III. ### Explanation The maintenance of blood fluidity within the normal vascular system is achieved through a delicate balance between procoagulants and natural anticoagulants. **Why Antithrombin III is correct:** Antithrombin III (AT-III) is the most important **natural circulating anticoagulant**. It is a serine protease inhibitor (serpin) that irreversibly inactivates several factors in the clotting cascade, most notably **Thrombin (Factor IIa)** and **Factor Xa**. It also inhibits Factors IXa, XIa, and XIIa. While it works independently to prevent spontaneous clot formation in normal vessels, its activity is increased several thousand-fold in the presence of heparin or heparin-like molecules on the endothelial surface. **Analysis of Incorrect Options:** * **Plasminogen (B):** This is the inactive precursor of plasmin. It is involved in **fibrinolysis** (dissolving an existing clot) rather than preventing the initial formation of a clot in the normal vascular system. * **Fibrinogen (C):** This is **Factor I**, a procoagulant. It is converted into fibrin by thrombin to form the structural mesh of a blood clot. * **Heparin (D):** While heparin is a potent anticoagulant, it is primarily found in the granules of mast cells and basophils. Endogenous heparin levels in normal circulating plasma are **negligible**; therefore, it does not function as the primary systemic anticoagulant under physiological conditions. It acts as a cofactor that enhances Antithrombin III. **High-Yield NEET-PG Pearls:** * **Antithrombin III Deficiency:** Leads to a hypercoagulable state (thrombophilia) and "Heparin Resistance," where standard doses of heparin fail to prolong the PTT. * **Protein C and S:** Other key natural anticoagulants; they specifically inactivate Factors Va and VIIIa. * **Virchow’s Triad:** Endothelial injury, stasis, and hypercoagulability are the three factors leading to intravascular thrombosis.

Q: Which substance is present in both serum and plasma?

Factor VII. To answer this question, one must understand the fundamental difference between **plasma** and **serum**: * **Plasma:** The liquid, cell-free part of blood that has been treated with anti-coagulants. It contains all clotting factors. * **Serum:** The liquid remains after blood has clotted. Therefore, **Serum = Plasma – Clotting Factors (I, II, V, VIII, XIII).** ### Why Factor VII is the Correct Answer During the coagulation process, certain clotting factors are entirely consumed to form the fibrin clot, while others remain in the serum. * **Factor VII** (Proconvertin) is a stable factor. While it participates in the extrinsic pathway, it is **not consumed** during the clotting process. Therefore, it remains present in both plasma and serum. ### Why the Other Options are Incorrect * **A. Fibrinogen (Factor I):** This is the precursor to fibrin. During clotting, fibrinogen is converted into fibrin threads to form the meshwork of the clot. Thus, it is absent in serum. * **C. Factor V (Proaccelerin):** This is a "labile factor" that is consumed during the formation of the prothrombinase complex. It is absent in serum. * **D. Factor II (Prothrombin):** This is converted into thrombin during the coagulation cascade. As it is used up to activate fibrinogen, it is absent in serum. ### NEET-PG High-Yield Pearls * **Consumed Factors (Absent in Serum):** Factors I, II, V, VIII, and XIII. (Mnemonic: "1, 2, 5, 8, 13 are used up"). * **Factors present in Serum:** VII, IX, X, XI, and XII. * **Vitamin K Dependent Factors:** II, VII, IX, and X. * **Most Stable Factor:** Factor VII (also has the shortest half-life). * **Labile Factors:** Factor V and Factor VIII (activity decreases rapidly in stored blood).

Q: Tissue thromboplastin activates which coagulation factor?

Factor VII. **Explanation:** The coagulation cascade is divided into the Intrinsic and Extrinsic pathways, which converge into a Common pathway. This question focuses on the **Extrinsic Pathway**, which is the primary initiator of blood clotting in vivo. **1. Why Factor VII is correct:** Tissue Thromboplastin (also known as **Factor III** or Tissue Factor) is released upon subendothelial vascular injury. It acts as a high-affinity receptor and cofactor for **Factor VII**. Once Tissue Thromboplastin binds to Factor VII, it activates it to Factor VIIa in the presence of calcium ions. This **Tissue Factor-Factor VIIa complex** then goes on to activate Factor X (the start of the common pathway) and Factor IX. **2. Why other options are incorrect:** * **Factor IV:** This refers to **Calcium ions (Ca²⁺)**. While calcium is a mandatory cofactor for almost all steps of the coagulation cascade (including the activation of Factor VII), it is not the factor "activated" by thromboplastin. * **Factor VI:** This factor is **non-existent** in the modern coagulation nomenclature. It was originally thought to be "accelerin" (activated Factor V), but it was later removed from the list once its identity was clarified. * **None of the above:** Incorrect, as Factor VII is the specific target of Tissue Thromboplastin. **Clinical Pearls for NEET-PG:** * **PT vs. aPTT:** The Extrinsic pathway (Factor VII) is clinically monitored using **Prothrombin Time (PT)**. The Intrinsic pathway is monitored using **aPTT**. * **Vitamin K Dependency:** Factor VII has the **shortest half-life** (approx. 6 hours) among the Vitamin K-dependent factors (II, VII, IX, X). Therefore, PT is the first lab value to become prolonged in Vitamin K deficiency or early Warfarin therapy. * **Initiation:** Remember that the Extrinsic pathway is "extrinsic" because it requires a factor (Tissue Thromboplastin) normally found outside the blood.

Q: Increased Prothrombin time results from deficiency of which factor?

Fibrinogen. **Explanation:** Prothrombin Time (PT) measures the integrity of the **Extrinsic** and **Common pathways** of the coagulation cascade. It specifically assesses Factors **I (Fibrinogen)**, **II (Prothrombin)**, **V**, **VII**, and **X**. 1. **Why Fibrinogen is correct:** Fibrinogen (Factor I) is the final substrate of the common pathway. Since PT measures the time taken for a fibrin clot to form, a significant deficiency in Fibrinogen will lead to a prolonged PT. 2. **Why Factor IX and XI are incorrect:** These factors belong to the **Intrinsic pathway**. Deficiencies in Factors VIII, IX, XI, or XII result in a prolonged **Activated Partial Thromboplastin Time (aPTT)**, while the PT remains normal. 3. **Why Factor VI is incorrect:** There is no "Factor VI" in the modern coagulation cascade (it was previously thought to be activated Factor V but was later removed from the nomenclature). **Clinical Pearls for NEET-PG:** * **PT** is the most sensitive screening test for **Vitamin K deficiency** and **Liver disease** because it monitors Factor VII, which has the shortest half-life (approx. 6 hours). * **Warfarin** therapy is monitored using PT/INR (Extrinsic pathway). * **Heparin** therapy is monitored using aPTT (Intrinsic pathway). * **Isolated prolonged PT** usually indicates Factor VII deficiency. * **Prolongation of both PT and aPTT** suggests a deficiency in the common pathway (Factors I, II, V, or X).

Q: Although more than 400 blood groups have been identified, the ABO Rh blood group systems remain the most important in clinical medicine because?

A, B and Rh antigens are most immunogenic.. ### Explanation The clinical significance of a blood group system is determined by its **immunogenicity**—the ability of an antigen to provoke an immune response (antibody production). **1. Why Option C is Correct:** While hundreds of antigens exist on the erythrocyte surface, the **A, B, and D (Rh) antigens** are the most potent immunogens. In the ABO system, individuals naturally possess pre-formed "isoagglutinins" (antibodies) against the antigens they lack. In the Rh system, although antibodies are not naturally occurring, the D-antigen is so highly immunogenic that an Rh-negative individual exposed to even a small amount of Rh-positive blood has an 80% probability of developing anti-D antibodies. This leads to severe **Acute Hemolytic Transfusion Reactions** or **Hemolytic Disease of the Fetus and Newborn (HDFN)**. **2. Why Other Options are Incorrect:** * **Option A:** Being the first identified (by Landsteiner in 1900) is a historical fact, not a clinical reason for its importance. * **Option B:** The number of phenotypes (four in ABO) does not dictate clinical risk; many minor systems have multiple phenotypes but rarely cause reactions. * **Option D:** All blood group antigens (Kell, Duffy, Kidd, etc.) are inherited via Mendelian genetics; this is not a unique feature of the ABO/Rh systems. **3. High-Yield Clinical Pearls for NEET-PG:** * **Landsteiner’s Law:** States that if an agglutinogen (antigen) is present on RBCs, the corresponding agglutinin (antibody) must be absent from the plasma (applies strictly to the ABO system). * **Universal Donor:** O Negative (no A, B, or D antigens). * **Universal Recipient:** AB Positive (no anti-A, anti-B, or anti-D antibodies). * **Bombay Blood Group (Oh):** Lacks the H-antigen; these individuals produce anti-H antibodies and can only receive blood from another Bombay phenotype donor. * **Most Immunogenic Rh Antigen:** D > c > E > C > e.

Q: Which of the following factors is NOT derived from endothelial cells?

Thromboxane A2. **Explanation:** The correct answer is **Thromboxane A2 (TXA2)**. The vascular endothelium plays a dual role in hemostasis, primarily maintaining an anti-thrombotic surface under physiological conditions while facilitating coagulation upon injury. **1. Why Thromboxane A2 is the correct answer:** Thromboxane A2 is a potent vasoconstrictor and platelet aggregator. It is synthesized and released primarily by **activated platelets** (via the cyclooxygenase pathway), not by endothelial cells. Its primary function is to promote clot formation, opposing the effects of endothelial-derived factors. **2. Why the other options are incorrect:** * **Thrombomodulin:** This is a specific receptor expressed on the **luminal surface of endothelial cells**. It binds to thrombin, converting it from a procoagulant enzyme into an anticoagulant that activates Protein C. * **Protein S:** While primarily synthesized in the liver, Protein S is also synthesized and secreted by **vascular endothelial cells** and megakaryocytes. It acts as a non-enzymatic cofactor for activated Protein C (APC). * **Prostacyclin (PGI2):** This is the major prostaglandin synthesized by **endothelial cells**. It is a potent vasodilator and inhibitor of platelet aggregation, acting as a physiological antagonist to Thromboxane A2. **High-Yield Clinical Pearls for NEET-PG:** * **The PGI2:TXA2 Balance:** In health, the endothelium-derived PGI2 inhibits platelet aggregation. In endothelial injury, this balance shifts toward TXA2, favoring clot formation. * **Other Endothelial Products:** Nitric Oxide (vasodilator), von Willebrand Factor (vWF - stored in Weibel-Palade bodies), and Tissue Plasminogen Activator (t-PA). * **Aspirin Mechanism:** Low-dose aspirin irreversibly inhibits COX-1 in platelets, reducing TXA2 levels. Since platelets lack a nucleus, they cannot synthesize new enzymes, leading to a prolonged anti-platelet effect.

Question 1

Oedema occurs when plasma protein level is below which value?

Accepted Answer

5 mg/dl

Answer

8 mg/dl

Answer

2 mg/dl

Answer

10 mg/dl

Question 2

Which of the following anticoagulants prevent clotting of blood in the normal vascular system?

Accepted Answer

Antithrombin III

Answer

Plasminogen

Answer

Fibrinogen

Answer

Heparin

Question 3

Which substance is present in both serum and plasma?

Accepted Answer

Factor VII

Answer

Fibrinogen

Answer

Factor V

Answer

Factor II

Question 4

A patient with mild congestive heart failure is treated with high-dose furosemide and diuresis of fluid. A complete blood count (CBC) taken before the diuresis shows an RBC count of 4 million/mm3; a CBC taken after diuresis shows a RBC count of 7 million/mm3. Which of the following is the most likely explanation?

Accepted Answer

Relative polycythemia

Answer

Cyanotic heart disease

Answer

Increased erythropoietin

Answer

Polycythemia vera

Question 5

Tissue thromboplastin activates which coagulation factor?

Accepted Answer

Factor VII

Answer

Factor IV

Answer

Factor VI

Answer

None of the above

Question 6

Increased Prothrombin time results from deficiency of which factor?

Accepted Answer

Fibrinogen

Answer

Factor IX

Answer

Factor VI

Answer

Factor XI

Question 7

The biconcave shape of RBC is useful in all aspects except:

Accepted Answer

Helps in cellular metabolism

Answer

Helps in passing through capillaries

Answer

Increased surface area for gas diffusion

Answer

Prevents osmotic lysis

Question 8

Although more than 400 blood groups have been identified, the ABO Rh blood group systems remain the most important in clinical medicine because?

Accepted Answer

A, B and Rh antigens are most immunogenic.

Answer

It was first identified.

Answer

It has four different types of blood groups.

Answer

They are inherited.

Question 9

Which of the following factors is NOT derived from endothelial cells?

Accepted Answer

Thromboxane A2

Answer

Thrombomodulin

Answer

Protein S

Answer

Prostacyclin

Question 10

Vesicular transmission of antibody can occur in all of the following, EXCEPT?

Accepted Answer

Neonatal toxic erythema

Answer

Rh incompatibility

Answer

Isoimmune thrombocytopenia

Answer

Neonatal myasthenia gravis

Blood and Immunity — MCQs

Blood and Immunity — MCQs

On this page

Practice by Chapter

Want unlimited practice?